Director/PDMR Shareholding

RNS Number : 1520P

Advanced Oncotherapy PLC

04 June 2015

 

4 June 2015

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Director Dealing

The Company announces that Michael Sinclair, Executive Chairman of the Company, had yesterday purchased an option over 30 million ordinary shares of 1 penny each in the Company ("Ordinary Shares") from Brahma AG at a cost of £300,000 ("Option"). The Option vests immediately, expires two years from today's date and has an exercise price of 10p per Ordinary Share.

Following the above transaction, Michael Sinclair's interest in the Company is as follows:

Ordinary Shares:                                                68,079,757

Options over Ordinary Shares:                     65,800,000

Warrants over Ordinary Shares:                  28,500,000

For further information contact:

Advanced Oncotherapy Plc	www.avoplc.com
Sanjeev Pandya, CEO	Tel: [phone]
Nicholas Serandour, CFO
Westhouse Securities (Nomad & Joint Broker)	Tel: [phone]
Antonio Bossi / David Coaten
Beaufort Securities (Joint Broker)	Tel: [phone]
Saif Janjua / Jon Levinson
Walbrook PR (Financial PR & IR)	Tel: [phone] or [e-mail]
Paul McManus / Anna Dunphy	Mob: [phone] / Mob: [phone]

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy's team based at CERN in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects. Therefore, the disruptive technology of the Company changes the financial model of proton therapy now that LIGHT is expected to have a comparable cost to conventional radiotherapy.

The Company has signed a purchase agreement with Sinophi Healthcare Limited for one LIGHT proton therapy system to be installed in a hospital in China and has further Letters of Intent from other healthcare providers.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END

 

 

RDSBUGDLIUGBGUX